Compare Akamai Technologies, Inc. (AKAM) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Akamai Technologies, Inc. vs Medpace Holdings Inc — how do they compare? Akamai Technologies, Inc. trades at $127.5 (market cap $16.63B), while Medpace Holdings Inc trades at $531.77 (market cap $15.60B). The key difference: Akamai Technologies, Inc. and Medpace Holdings Inc are close in size by market cap. Which is the better fit depends on your goals.
| AKAM | MEDP | |
|---|---|---|
Market Cap | $16.63B | $15.60B |
Sector | Technology | Technology |
52-Week High | $161.14 | $620.59 |
52-Week Low | $70.53 | $308.88 |
Enterprise Value | $21.56B | $15.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $114.37, up 1.06% on the day but down significantly from its 26-year high of $165.45 in May 2026. The stock faces a bearish technical signal despite recent earnings beats. Revenue growth has slowed to 5% annually, with net income margin declining from 14.47% in 2022 to 10.74% in 2025. The company continues strategic moves in cybersecurity, completing the LayerX acquisition and expanding its NVIDIA partnership for AI security.
While analyst consensus remains positive with a $170.20 price target, near-term headwinds include declining profitability, high valuation multiples, and competitive pressures. The stock's current pullback presents a potential entry point for long-term investors believing in its cybersecurity and cloud computing positioning, though execution risks and margin compression require monitoring.
Medpace (MEDP) trades at $565.09, up 1.34% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, 17.19% net margins, and robust ROE of 77.25%. Recent news highlights shifting CRO demand dynamics and upcoming Q2 2026 earnings on July 22. The stock trades near 52-week highs with technical indicators showing overbought conditions.
MEDP presents growth potential from steady revenue expansion and strong profitability, though elevated valuations (P/E 35.59) and class action lawsuits pose risks. Analyst consensus leans cautious with 63% hold ratings and $465 price target below current levels. The stock's upside depends on continued earnings outperformance and backlog quality improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
